Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
2021
2021
2023
2023
2023
2023
Eligo develops first-in-class proprietary modalities that enable the delivery and expression of therapeutic DNA in target bacterial populations of the microbiome. This technology allows for the first time the in-situ modulation of the microbiome’s composition and function to address human disease with an unprecedented precision.
2023
2023
QurAlis is a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
2022
2022
2022
2022
A biotechnology company identifying and targeting novel mechanisms to remove cancer's barriers to normal immunity.
2021
2021
Developing first-in-class therapeutics targeting 12-Lipoxygenase for heparin-induced thrombocytopenia and other immune-mediated disorders
2019
2020 - 2021
2020 - 2021
2016 - 2020
2018 - 2020
As a Senior Associate, I focused on orphan diseases, including orphan ophthalmology and neuromuscular disorders. RA Capital Management (“RA Capital”) is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes in a continual effort to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides RA Capital’s investment team and portfolio companies with strategic intelligence, market research, and other resources. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, public market dynamics, and many other factors on valuation and business viability.
2016 - 2018